Linda Nguyen, MD
Endocrinology, Diabetes & Metabolism · Rockville, MDNPI 1407104813
Payments from drug & device makers
Across 129 payments — averaging $24.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$435
- Novo Nordisk$324
- Amgen$275
- Abbott$249
- Tandem Diabetes Care, Inc.$235
- Boehringer Ingelheim$165
- plus $1K from 25 others
What the payments were for
- Consulting fees$261%
- Food & beverage$3,12399%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 21 | $435 |
| Novo Nordisk | 13 | $324 |
| Amgen | 11 | $275 |
| Abbott | 12 | $249 |
| Tandem Diabetes Care, Inc. | 7 | $235 |
| Boehringer Ingelheim | 5 | $165 |
| AbbVie(2 entities) | 8 | $153 |
| Radius Health, Inc. | 6 | $142 |
| Johnson & Johnson | 1 | $132 |
| IBSA Pharma Inc. | 5 | $116 |
| Boston Scientific | 1 | $93 |
| Ultragenyx Pharmaceutical Inc. | 1 | $80 |
| Insulet Corporation | 3 | $74 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Amneal Pharmaceuticals LLC | 4 | $70 |
| Ascendis Pharma Endocrinology Inc | 2 | $53 |
| AstraZeneca | 3 | $50 |
| Lifescan, Inc. | 2 | $48 |
| Dexcom, Inc. | 2 | $43 |
| Intercept Pharmaceuticals, Inc. | 2 | $43 |
| Pfizer | 3 | $42 |
| Averitas Pharma Inc. | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Medtronic | 2 | $33 |
| Bayer | 2 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $16 |
| Cequr Corporation | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$132
- CARVYKTI$132
- t-slim insulin pump$109
- EVENITY$102
How this compares
$3,149 in reported general payments places this provider in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 226 | $476,488 |
| TrulicityDulaglutide | 126 | $238,002 |
| JardianceEmpagliflozin | 124 | $184,224 |
| MounjaroTirzepatide | 72 | $140,946 |
| FarxigaDapagliflozin Propanediol | 51 | $50,531 |
| JanuviaSitagliptin Phosphate | 32 | $37,834 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $31,912 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $30,799 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $25,272 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $23,123 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $22,594 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $18,091 |
| Humalog Kwikpen U-100Insulin Lispro | 47 | $17,875 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $16,184 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $12,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $324 | $476,488226 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $435 | $386,126226 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $165 | $223,003148 claims |
| MerckJanuvia, Janumet Xr | $13 | $55,92549 claims |
| AstraZenecaFarxiga | $50 | $50,53151 claims |
| AbbVieSynthroid | $153 | $5,17462 claims |
| IBSA Pharma Inc.Tirosint | $116 | $3,63116 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $70 | $3,257301 claims |
| Sanofi-aventis U.S. LLCLantus | $71 | $1,86612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Rockville
- Michael DempseyRockville$2.7M
- Helena RodbardRockville$2.4M
- David BrownRockville$497K
- Gerti TashkoRockville$106K
- Jie HeRockville$26K
- Monika MannanRockville$8K
- Jean ParkBaltimore$3.7M
- Ilias SpanakisBaltimore$2.6M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.